Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.
McFarlane
Samy I
SI
Division of Endocrinology, Diabetes and Hypertension, State University of New York Health Science Center and Kings County Hospital Center, Brooklyn, NY 11203, USA. smcfarlane@downstate.edu
Provilus
Alfrede
A
Shin
John J
JJ
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011236:Prediabetic State / Q000188:drug therapy*; D017257:Ramipril / Q000627:therapeutic use*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D017257:Ramipril